Skip to content
About Prolight
Market
Partnerships
Board of Directors and Management
Clinical Advisory Board
History
Cutting-edge technology
Vision & strategy
Products
Psyros™
MicroFlex
Patents
Investors
Press releases
Financial reports
CEO comment
Financial calendar
Stock information
AGM
Shareholders
Key figures
Corporate governance
Prospectus
Issuance page – warrants of series TO7
Media
Press releases
Investor letters
Media gallery
Presentations
Articles
Contact us
Menu
About Prolight
Market
Partnerships
Board of Directors and Management
Clinical Advisory Board
History
Cutting-edge technology
Vision & strategy
Products
Psyros™
MicroFlex
Patents
Investors
Press releases
Financial reports
CEO comment
Financial calendar
Stock information
AGM
Shareholders
Key figures
Corporate governance
Prospectus
Issuance page – warrants of series TO7
Media
Press releases
Investor letters
Media gallery
Presentations
Articles
Contact us
EN
SV
Press releases
Category
All
Regulatory
Non-Regulatory
Interim
Annual
Year
All
2024
2023
2022
2024
2024-10-09 08:00
Prolight obtains patent potentially representing a new business opportunity
2024-10-07 09:45
The exercise period for warrants of series TO7 in Prolight Diagnostics begins today
Regulatory
2024-10-03 18:45
The exercise price for the warrants of series TO7 in Prolight Diagnostics has been determined to SEK 0.12 per share
Regulatory
2024-09-30 15:40
Prolight Diagnostics publishes investor letter for september 2024
2024-09-26 08:30
Prolight showcases Psyros™ to global key opinion leaders in cardiology at 2024 Cardiac Markers Dialogue Meeting
Regulatory
2024-09-25 14:30
Prolight conducts business review at FlexMedical Solutions
2024-08-30 13:48
Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share
2024-08-28 08:00
Prolight Diagnostics publishes half-year report, 2024
Regulatory
MAR
2024-07-03 08:00
Prolight Diagnostics presents the Psyros system at ADLM, one of the world's largest and most important diagnostics congresses
Regulatory
2024-06-04 08:35
Warrants of series TO6 were exercised to approximately 44.8 percent and Prolight Diagnostics receives approximately SEK 9.8 million
Regulatory
MAR
Next